CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements concerning our business operations, and financial performance and conditions, as well as our plans, objectives, and expectations for our business operations and financial performance and conditions that are subject to risks and uncertainties. All statements other than those of historical fact are forward-looking statements.

These types of statements typically contain words such as “aim,” “anticipate,” “assume,” “believe,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “potential,” “positioned,” “predict,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends. Forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business, the industry in which we operate, and our management’s beliefs and assumptions.

These statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those estimated. The contents of this presentation should be considered in conjunction with the risk factors, warnings, and cautionary statements contained in the Company’s annual, quarterly, and other reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.
2023: INITIAL REVENUE GUIDANCE $105 - $110 MILLION

Revenue and Margin Expected to Scale Through Year, Driving Business Units to Cash Positive in 2024

### VLN® executing aggressive 2023 multi-state commercial launch program
- Exceptional product demand drives market share accumulation
- Readying to add thousands of new retail locations in CA, TX & FL
- More than 100 chains in the funnel, scheduling launches rest of 2023

### GVB dominating ingredient, manufacturing and distribution roles
- Continued record ingredient volume drives market leading position
- $140 million in exclusive CDMO+D agreements with two major brands
- Bringing on new distillate production facilities in Prineville, OR

### New 2023 revenue guidance confirms growth outlook
- Expecting $105 - $110 million in sales, +69% to +77% YoY
- Improving margin and operating performance
- Clear path to cash positive in business units in 2024

---

**Revenue, net (in millions)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Tobacco</th>
<th>Hemp/Cannabis</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>$30.9 M</td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td>$40.5 M</td>
<td>$21.9 M</td>
</tr>
<tr>
<td>2023F</td>
<td>$62.4 M</td>
<td>$105 - $110M</td>
</tr>
</tbody>
</table>

- 4Q 2022 & 1Q 2023 Tobacco volumes reflects transition away from lower margin filtered cigar business to reallocate capacity to higher margin store brand CMO and VLN® business ahead of volume ramp
- Hemp/cannabis revenues grew on record ingredient volumes and increased contract manufacturing activity even after the November 2022 Grass Valley fire
2023 REVENUE RAMP DRIVES 2024 CASH POSITIVE GOAL

Both VLN® and Hemp/Cannabis Business Lines Benefit from Improved Operating Performance Drivers

Commercializing FDA MRTP Label for VLN® Reduced Nicotine Content Products

- Confirmed demand from both consumer and retail channels, updated marketing programs to support
- Secured #1, #2 national scale distributors, #3, #4 and regional in discussions
- Launching thousands of stores across largest U.S. state markets supported by updated marketing campaign; massive funnel of 100+ retailers in discussion or scheduling launches throughout rest of 2023
- Commercial rollout in up to 18 U.S. States in 2023 represents 600+ million cartons of addressable market
- Shifting mix toward higher margin store brand CMO and VLN® volumes will increase operating profit
- Cash positive operations for tobacco business by second half 2024, including corporate overhead

Rapidly Scaling GVB Cannabinoid Ingredient, API and CDMO Market Leadership

- Accelerating across 3 distinct growth drivers and profit centers
  - Record ingredient volumes as dominant share leader in North America
  - Increased demand and new agreements drive CDMO volume growth
  - Multiple new exclusive fully verticalized sales and distribution agreements with major brands
  - In-house growing, extraction and new distillation facilities will increase operating profit
  - Cash positive operations for hemp/cannabis business by first half of 2024, including corporate overhead

1. Grandview Research; https://www.grandviewresearch.com/industry-analysis/us-tobacco-market#:~:text=The%20U.S.%20tobacco%20market%20was%20estimated%20at%20USD%2075.9%2C%20USD%2078.3%2C%20billion%2C%202022
FDA Authorized VLN®
Cannabinoid Ingredients,
APIs and CDMO
Corporate/Financial
12 MONTHS OF VLN®:
FROM FIRST SALES TO MAJOR MULTI-STATE LAUNCH

One year ago, VLN® was less than 30 days into the pilot, announcing its first sales April 13, 2022

Exceptional early sales and consumer interest exceeded all industry expectations

New tobacco team has upgraded VLN’s launch plans since December 2022 to best take advantage of consumer and retail interest

Now moving into full commercialization as a mainstream disruptor with clear path to cash positive in 2H 2024

VLN allows consumers to literally stare smoke in the face and say, “I don’t need you.”
NEW VLN® LAUNCH IN TOP CA, TX AND FL MARKETS

2023 VLN® Expansion Now Underway, Retail Chains Booking Launches Throughout the Year

Example VLN® Distribution: MRTP States + Adjacent States

- Announced Launch State
- Prospective Expansion State

8 States Announced; Targeting VLN® Sales in up to 18 States by End of 2023

Rapidly Accelerating Commercial Rollout

18 Targeted Markets, 56% of Total U.S. Cigarette Sales

<table>
<thead>
<tr>
<th>State</th>
<th>% of Adult Smokers</th>
<th>Pack Volume</th>
<th>Retail Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZ</td>
<td>15%</td>
<td>160M</td>
<td>$1.4B</td>
</tr>
<tr>
<td>CA</td>
<td>10%</td>
<td>514M</td>
<td>$4.9B</td>
</tr>
<tr>
<td>CO*</td>
<td>14%</td>
<td>130M</td>
<td>$1.0B</td>
</tr>
<tr>
<td>FL</td>
<td>15%</td>
<td>513M</td>
<td>$3.9B</td>
</tr>
<tr>
<td>IL</td>
<td>15%</td>
<td>253M</td>
<td>$2.6B</td>
</tr>
<tr>
<td>NM*</td>
<td>16%</td>
<td>48M</td>
<td>$0.4B</td>
</tr>
<tr>
<td>TX</td>
<td>15%</td>
<td>736M</td>
<td>$5.6B</td>
</tr>
<tr>
<td>UT*</td>
<td>8%</td>
<td>45M</td>
<td>$0.4B</td>
</tr>
<tr>
<td>WI</td>
<td>15%</td>
<td>184M</td>
<td>$1.6B</td>
</tr>
<tr>
<td>CT*</td>
<td>12%</td>
<td>65M</td>
<td>$0.8B</td>
</tr>
<tr>
<td>GA</td>
<td>16%</td>
<td>398M</td>
<td>$2.5B</td>
</tr>
<tr>
<td>IN</td>
<td>19%</td>
<td>328M</td>
<td>$2.3B</td>
</tr>
<tr>
<td>KY*</td>
<td>24%</td>
<td>295M</td>
<td>$2.0B</td>
</tr>
<tr>
<td>MI*</td>
<td>19%</td>
<td>351M</td>
<td>$2.9B</td>
</tr>
<tr>
<td>NC*</td>
<td>19%</td>
<td>500M</td>
<td>$3.3B</td>
</tr>
<tr>
<td>NY</td>
<td>13%</td>
<td>180M</td>
<td>$2.2B</td>
</tr>
<tr>
<td>OH</td>
<td>21%</td>
<td>467M</td>
<td>$3.7B</td>
</tr>
<tr>
<td>SC</td>
<td>18%</td>
<td>215M</td>
<td>$1.5B</td>
</tr>
<tr>
<td>Total</td>
<td>-</td>
<td>2,397M</td>
<td>$20.2B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>State</th>
<th>% of Adult Smokers</th>
<th>Pack Volume</th>
<th>Retail Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>WI</td>
<td>15%</td>
<td>184M</td>
<td>$1.6B</td>
</tr>
<tr>
<td>CT*</td>
<td>12%</td>
<td>65M</td>
<td>$0.8B</td>
</tr>
<tr>
<td>GA</td>
<td>16%</td>
<td>398M</td>
<td>$2.5B</td>
</tr>
<tr>
<td>IN</td>
<td>19%</td>
<td>328M</td>
<td>$2.3B</td>
</tr>
<tr>
<td>KY*</td>
<td>24%</td>
<td>295M</td>
<td>$2.0B</td>
</tr>
<tr>
<td>MI*</td>
<td>19%</td>
<td>351M</td>
<td>$2.9B</td>
</tr>
<tr>
<td>NC*</td>
<td>19%</td>
<td>500M</td>
<td>$3.3B</td>
</tr>
<tr>
<td>NY</td>
<td>13%</td>
<td>180M</td>
<td>$2.2B</td>
</tr>
<tr>
<td>OH</td>
<td>21%</td>
<td>467M</td>
<td>$3.7B</td>
</tr>
<tr>
<td>SC</td>
<td>18%</td>
<td>215M</td>
<td>$1.5B</td>
</tr>
<tr>
<td>Total</td>
<td>-</td>
<td>6,159M</td>
<td>$43.0B</td>
</tr>
</tbody>
</table>

- Announced
- Priority States

| Source: | CDC; Current Cigarette Use Among Adults (Behavior Risk Factor Surveillance System) 2019; World Population Review Cigarette Prices by State; Internal Documents |

- Secured #1, #2 national scale c-store distributors; In process with #3, #4, regionals
- Readying to launch with major c-store chain in CA, TX, FL; #2 C-store chain on board in IL, CO
- Adding new national and regional c-store chains in key states
- Scaling initial 500 stores in 2 states with 4,000+ stores in 3 new states
- More than 100 chains in pipeline interested in VLN®, plus additional distribution

*State with MRTP Tax Benefit
Our recent research produced two very important findings that VLN, and NOT other reduction/cessation products, can take advantage of:

1. Smokers are addicted to the act of smoking, not just nicotine
2. Current cessation messaging and products are perceived negatively and make smokers feel less confident and competent, potentially discouraging reduction and cessation

Our recent research showed that VLN was the preferred method for smoking reduction because it doesn’t force smokers to quit the behavior “cold turkey.”

Our new campaign is designed to establish this VLN Advantage:

1. Reinforce the fact that they don’t have to quit “cold turkey”
2. Optimistically encourage them to try VLN
3. Inspire confidence and competence
4. Entice them to learn more about VLN and how it can help them

VLN® READY TO LAUNCH NEW CAMPAIGN SPECIFICALLY DESIGNED TO EVOKE TRIAL AND REPEAT PURCHASE

VLN Has Real Competitive Advantages that Support Commercial Success
CAMPAIGN SUPPORTED THROUGH TARGETED PAID MEDIA

Hyper-Targeted Media Blitzes in Rollout Markets Will Reach Prospects through Multiple Digital Touchpoints Generating Top-of-Mind Awareness, VLN Advantage Education and Retail Foot Traffic

Advanced targeting techniques ensure most efficient programs are in market, strong penetration against key target segments and high message frequency for brand name recognition

- Program will run on content that has an age composition of at least 85% age 21+
- Combination of online video, large-format display banners and dynamic native ads engage prospects, reinforce brand’s value proposition and increase product credibility
- Dollars focused within priority zip-codes based on high concentration of adult consumers and retailers

Campaign success will be measured by a third-party pre/post brand awareness study and retail foot traffic measurements to allow for real-time media optimizations
ONGOING ACTIVITY DELIVERS CONTINUOUS ENGAGEMENT

Integrated Efforts Will Keep VLN in Front of Consumers and Business Partners with a Consistent Message to Grow the Brand

**Brand Website**
Revamped website will deliver education, user testimonials, smoking reduction support tools and consistently updated articles to attract consumers and fuel organic search.

**Brand Community**
Interested consumers will receive ongoing communication with news, information and offers to help keep them on their reduction journey with VLN.

**Enhanced PR Efforts**
Local market advocates are being engaged to speak out in support of VLN’s mission and product. Proactive media relations underway to create incremental market level paid and earned media opportunities.

**Influencer**
Currently exploring macro and micro influencers to have a consistent stream of voices helping to educate and establish brand trust.
THE PROOF IS IN THE PINNACLE (LAUNCH)

Rapid Rollout to Hundreds of Stores Confirms Rapid Scalability for VLN® Distribution

Pinnacle is a conventional, premium, store brand cigarette for current adult smokers

Sold at a top 5 retail C-store chain, 1,700+ locations across 22 states

Leverages national scale distributor also being used for VLN® distribution and stocking

Initial sales demonstrated strong share gains on compelling value proposition and consistent availability, even ahead of in-store promotion

Demonstrates how XXII’s new distribution can launch VLN® into thousands of key c-store locations within weeks
Advancing pilot programs for additional markets in 2023, including expected:

- **Switzerland (pilot test)** – product shipped for distribution commencing by late May
- **Japan (pilot test)** – product readying for shipment to distributor ahead of test sales commencing in late June 2023
- **South Korea (updated product)** – updated packaging being designed in response to initial market tests, product expected to be shipped to the distributor in Summer 2023 for additional market testing
IMPROVING MIX TO ENHANCE CAPACITY AND MARGIN

Prioritizing Higher Margin CMO and VLN® Production to Support Increasing Demand

Shifting product mix at NASCO to improve operating results

Rotating out of lower margin filtered cigar volumes to free capacity for higher margin premium cigarettes

Specialty CMO products like Spectrum provide superior margin and more predictable demand patterns

VLN® provides premium margin opportunities and will require greater share of capacity as warehouse stocking and retail sales expand throughout 2023
VLN® CAN BE THE FOUNDATION FOR HARM REDUCTION POLICIES IN THE U.S. AND ABROAD

The science shows a **menthol ban** absent an off-ramp primarily transitions menthol smokers to traditional cigarettes, while a **reduced nicotine mandate** would help all smokers more easily quit smoking or migrate to less toxic products.

FDA continues to advance its scientifically based **menthol ban** and **reduced nicotine content policies**, plus state and local governments are taking direct action.

**VLN® Menthol King cigarettes** could be the **only** current combustible menthol cigarette potentially **exempt** from the menthol ban.

**New Zealand’s** reduced nicotine mandate takes effect in ~2 years – requires all cigarettes to be 0.8mg/g or less, including test variance.

**Seed development program** scaled to supply tobacco to the entire New Zealand market – more than 2 billion cigarettes in total.
VLN® PATH TO CASH POSITIVE 2024

Customers and Retailers WANT to Access VLN®

Expanded Major Distribution
- Agreements with #1, #2 U.S. c-store distributors accelerates launching thousands of stores across multiple states
- Provides access to stores within days or weeks after retailer agrees to carry VLN® or conventional products
- Adding international activity in South Korea, Japan, Switzerland

Onboarding Top Retail Partners
- Starting from ~500 stores across 2 core states
- Adding Pinnacle to ~1,700 stores in 20+ states during April and May
- Adding 4,000+ VLN® stores in CA, TX and FL starting in May
- Adding regional stores, expanding Smoker Friendly
- Pipeline of 100+ national and regional chains, scheduling launches throughout 2023

New Consumer Campaign
- Designed to inspire confidence, competence and optimism, VLN® provides a new path for smokers to take control and succeed in their reduction goals
- Activating influencers to create a consistent stream of voices supporting smokers’ decisions to reduce their habit

Optimizing Operations
- Transitioning capacity away from low margin filtered cigar business
- Scaling higher margin VLN and premium CMO products to meet increased store count and distributor stocking needs
- Upfront investment in sales team driving rapid market penetration and supports new CDMO+D license and distribution agreements

Expanded availability and supportive voices drive trial, repeat purchase and market share, leading to cash positive operations in 2024
FDA Authorized VLN®
Cannabinoid Ingredients,
APIs and CDMO
Corporate/Financial
22nd Century’s GVB Biopharma (“GVB”) is transforming the manufacturing and distribution of hemp-derived active ingredients and finished goods in the consumer products, nutraceutical and pharmaceutical industries.

Dominant North American position plus broad global footprint in geographic markets targeted for growth

- Record ingredient sales quarter after quarter
- New CDMO+D model expands revenue and adds value to customers
- New extraction unit, production facilities and plant biotechnology by 22nd Century will lead to margin expansion
- Contract farming increases biomass availability and stabilizes costs

- On track to achieve cash positive operations in first half 2024, including corporate allocation
DRIVING RECORD INGREDIENT SALES VOLUMES

Growing Volumes Sets Stage For Return To Internal Production, Margin Recovery

- GVB bulk ingredient volumes rising rapidly based on reputation as reliable supplier of consistent, quality extracts
- New campus expected to target capacity for 10 million lbs. hemp biomass and 600,000 kg of extracts annually, 100,000 kg dedicated top pharma grade

GVB bulk ingredient volumes (kgs)

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Volumes (kgs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1Q22</td>
<td>16,524</td>
</tr>
<tr>
<td>2Q22</td>
<td>26,546</td>
</tr>
<tr>
<td>3Q22</td>
<td>27,912</td>
</tr>
<tr>
<td>4Q22</td>
<td>41,070</td>
</tr>
<tr>
<td>1Q23</td>
<td>68,195</td>
</tr>
</tbody>
</table>
TRANSFORMATIVE NEW CDMO+D MODEL

First Two Agreements Signed With Estimated $140 Million Cumulative Sales Value Over Three-year Terms

Working with the largest and best-known consumer CBD brands

- Initial agreements with brand leaders like Cookies, Old Pal, and others in process
- License covers broad range of hemp derived cannabinoid consumer packaged goods at each brand

New, single-source model provides complete solution

- Ingredient Supply
- White-label manufacturing
- Retail category management and distribution

Enhances GVB revenue and margin opportunities with distribution services

- VLN® sales team and channel to place products with retailers seeking innovative, high velocity, high margin, small footprint consumer CBD products
GVB POSITIONED FOR GLOBAL LEADERSHIP

Industry Leading Certifications Position GVB as the Supplier of Choice

FDA’s Commitment to Advance Regulatory Standards and Product Recommendations on CBD Use in Consumer and Nutraceutical Products will Further Expand the Market

**Prineville, Oregon:** World-scale crude extraction over 15,000 kg/month at full capacity (operational Q1 2023); New ingredient and production and refinement facility with increased capacity and greater efficiency

**Las Vegas, Nevada:** 40,000 sq. ft. CDMO facility used for Private Label/Contract Manufacturing

**United Kingdom:** RXP acquisition creates leadership position in novel foods applications market

**European Union:** Netherlands Distribution provides increased availability to higher margin customers

Filed FDA DMF to provide pharmaceutical grade API differentiating GVB distillates and isolates
HEMP/CANNABIS PATH TO CASH POSITIVE 2024

Rapid scale plus operating enhancements create clear path to profitability

Operating Performance Enhancement

- Resume in-house distillate and isolate production
- New CBD crude extraction and biomass cultivation to drive incremental margin
- Scale revenue and increase gross margin across fixed cost base

Scale CDMO+D Business Volumes

- New white label plus distribution agreements establish new business model in industry
- Deep vertical integration drives further margin opportunity
- Robust pipeline of follow-on peer contract opportunities

FDA Drug Master File

- Growing number of CBD pharmaceutical trial activities represents new, high-value addressable market
- Completed FDA DMF filing to access pharmaceutical grade market currently dominated by high-cost synthetic products

Food & Nutraceuticals Market Expansion

- New FDA guidelines will establish enhanced regulatory standards and validate the market
- Extensive certification and standardization capabilities distinguish GVB from smaller producers

Continued revenue growth plus improving margin and operating performance will drive hemp/cannabis to cash positive operations in 2024
FDA Authorized VLN®
Cannabinoid Ingredients,
APIs and CDMO
Corporate/Financial
## FIRST QUARTER 2023 FINANCIAL HIGHLIGHTS

<table>
<thead>
<tr>
<th></th>
<th>Net Revenues (Q1 2023)</th>
<th>Gross Profit¹ (Q1 2023)</th>
<th>Gross Margin¹ (Q1 2023)</th>
<th>Operating Loss (Q1 2023)</th>
<th>Adjusted EBITDA² (Q1 2023)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1Q 2023</strong></td>
<td>$22.0M</td>
<td>$(1.2)M</td>
<td>(5.4)%</td>
<td>$(17.8)M</td>
<td>$(14.7)M</td>
</tr>
<tr>
<td><strong>1Q 2022</strong></td>
<td>$9.0M</td>
<td>$309K</td>
<td>3.4%</td>
<td>$(8.1)M</td>
<td>$(6.6)M</td>
</tr>
</tbody>
</table>

* +144% YoY increase in Net Revenues primarily due to GVB acquisition.

### Introducing 2023 full year revenue outlook for net revenues of $105 million to $110 million:
- Net revenues expected to scale steadily through 2023 driven by increased VLN® sales, growing GVB bulk ingredient revenue and new CDMO+D license agreements
- Gross profit projected to improve significantly in Q2 2023 and going forward reflecting
  - higher product mix in tobacco and
  - return of production capabilities, farming program and new CDMO+D contracts for hemp/cannabis
- 22nd Century on pace to achieve cash positive business unit operations in 2024

1. Gross profit margin is calculated by dividing gross profit by net revenues.
2. See the tables included in this release for a reconciliation of Adjusted EBITDA (a non-GAAP measure) to net loss.
## TOBACCO REVENUE & PROFIT BREAKDOWN

<table>
<thead>
<tr>
<th>Tobacco</th>
<th>1Q 2023</th>
<th>1Q 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unit sales¹</td>
<td>1.0M</td>
<td>1.4M</td>
</tr>
<tr>
<td>Net revenue</td>
<td>$8.9M</td>
<td>$9.0M</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$18K</td>
<td>$309K</td>
</tr>
<tr>
<td>Gross profit margin²</td>
<td>0.2%</td>
<td>3.4%</td>
</tr>
</tbody>
</table>

- Net revenues decreased slightly QoQ reflecting a planned reallocation in production resources at the Company’s NASCO facilities away from lower margin filtered cigars to higher margin VLN® and conventional cigarette products.
- Gross profit declines QoQ reflecting the transition.

### Opportunity in 2023 for additional tobacco net revenue growth and margin expansion:

- New Pinnacle launch scaling rapidly, creating new sales volumes.
- Increased sales volume of higher margin CMO cigarette products in place of lower margin filtered cigar volumes.
- Accelerated VLN® launch driving increased revenue and margin contribution from premium VLN® products.

1. Tobacco unit sales volume is measure in cartons
2. Gross profit margin is calculated by dividing gross profit by net revenues
3. Contract manufacturing operations (CMO)
HEMP/CANNABIS REVENUE & PROFIT BREAKDOWN

Net revenue growth QoQ primarily driven by:

- Addition of acquired GVB revenue contribution
- Significant GVB organic revenue volume growth QoQ
- 1Q net revenue increased despite 4Q Grass Valley fire
- Strong consumer demand for GVB bulk ingredients and new CDMO opportunities

### Hemp/Cannabis

<table>
<thead>
<tr>
<th></th>
<th>1Q 2023</th>
<th>1Q 2022(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unit sales(^1)</strong></td>
<td>68,195</td>
<td>16,524</td>
</tr>
<tr>
<td><strong>Net revenue</strong></td>
<td>$13.0M</td>
<td>$7.0M</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>$(1.2M)</td>
<td>$1.0M</td>
</tr>
</tbody>
</table>

1. Hemp/cannabis unit sales volume is measured as kilograms.
2. GVB acquisition occurred on May 13, 2022. All prior period results are provided for illustrative purposes only. These pro forma results do not purport to be indicative of the results that would have been obtained, or to be a projection of results that may be obtained in the futures. Refer to our Annual Report on Form 10-K Note 2 of the Consolidated Financial Statements for description of pro forma adjustments as required under U.S. GAAP.

Additional 2023 hemp/cannabis opportunity driven by:

- Organic growth reflecting continued strong customer demand for ingredient volumes and manufacturing support
- Contracted farming to produce internally-sponsored biomass at lower cost
- New CDMO+D license agreements beginning initial distribution activities
- Profit margin expansion reflecting full restoration of GVB extraction capabilities and vertical integration with new Prineville crude extraction facility becoming fully operational
## SUMMARY BALANCE SHEET ITEMS

<table>
<thead>
<tr>
<th>(in millions)</th>
<th>Balance sheet date as of:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1 2023</td>
<td>Year End 2022</td>
</tr>
<tr>
<td>Cash and cash equivalents¹</td>
<td>$23.7</td>
<td>$21.2</td>
</tr>
<tr>
<td>Total assets</td>
<td>$124.1</td>
<td>$114.7</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>$42.7</td>
<td>$18.7</td>
</tr>
<tr>
<td>Total shareholders' equity</td>
<td>$81.4</td>
<td>$96.0</td>
</tr>
</tbody>
</table>

¹. Cash, cash equivalents, short-term investment securities and restricted cash.

New $21.1M Credit Facility strengthens balance sheet and provides working capital to fund strong growth for both VLN and hemp/cannabis business.

Collected $5M of casualty loss insurance proceeds from the Grass Valley fire during Q1 23. Anticipated additional business interruption insurance proceeds estimated at approximately $8 million beginning in Q2 23.

Strengthened balance sheet supports growing working capital needs driven by increased VLN® product shipments to multiple national-scale distribution partners as well as strong customer demand for hemp/cannabis bulk ingredients.
Leveraging exceptional VLN® demand into aggressive multi-state commercial launch program
- Launching national scale distribution to support demand from largest C-Store, consumer, and pharmacy chains
- Selling VLN® in up to 18 states in 2023

Increased volumes and new market opportunities drive hemp/cannabis growth and margin
- Scaling ingredient and CDMO business in U.S. and Europe; launched CDMO+D model
- Submitted Drug Master File to FDA to produce and supply APIs for new medical and pharmaceutical industry

Confirmed path to cash positive in both tobacco and hemp/cannabis
- Executing clearly delineated revenue growth strategies in both business units
- Advancing to positive cash flow from hemp/cannabis and VLN® business units in 2024, including corporate overhead
Questions & Answers

INVESTOR RELATIONS & MEDIA CONTACT

Matt Kreps
Investor Relations
22nd Century Group, Inc.
+1-214-597-8200
mkreps@xxiicentury.com